(Q51937677)

18 April 2018

title

Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder. (English)

1 reference

18 April 2018

obsessive-compulsive disorder

1 reference

1 reference

2

1 reference

18 April 2018

Eric A Storch

1

Eric A Storch

1 reference

18 April 2018

Tanya Murphy

5

Tanya K Murphy

1 reference

18 April 2018

Wayne K. Goodman

8

Wayne K Goodman

1 reference

18 April 2018

Gary Roy Geffken

6

Gary R Geffken

1 reference

18 April 2018

author name string

Nathan A Shapira

3

1 reference

18 April 2018

Herbert E Ward

4

1 reference

18 April 2018

Holly Valerio

7

1 reference

18 April 2018

publication date

1 January 2006

1 reference

18 April 2018

published in

Depression and Anxiety

1 reference

18 April 2018

volume

23

1 reference

18 April 2018

page(s)

429-433

1 reference

18 April 2018

issue

7

1 reference

18 April 2018

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

cites work

1 reference

The epidemiology of obsessive-compulsive disorder in five US communities.

21 January 2018

1 reference

Quality of life for patients with obsessive-compulsive disorder.

21 January 2018

1 reference

Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal

21 January 2018

1 reference

Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy

21 January 2018

1 reference

7 January 2021

Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder

1 reference

7 January 2021

Drug treatment of panic disorder: early response to treatment as a predictor of final outcome

1 reference

7 January 2021

Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study

1 reference

7 January 2021

The changing prevalence and severity of obsessive-compulsive disorder criteria from DSM-III to DSM-IV.

1 reference

7 January 2021

Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study

1 reference

7 January 2021

A score for predicting response to pharmacotherapy in obsessive-compulsive disorder

1 reference

7 January 2021

Axis I and II comorbidity in a large sample of patients with obsessive-compulsive disorder.

1 reference

7 January 2021

Early treatment response in anxious outpatients treated with diazepam.

1 reference

7 January 2021

Clinical predictors of drug response in obsessive-compulsive disorder.

1 reference

7 January 2021

A rating scale for depression

1 reference

7 January 2021

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

1 reference

7 January 2021

The antiobsessional effects of clomipramine do not require concomitant affective disorder

1 reference

7 January 2021

Initial improvement as a criterion for drug choice in acute schizophrenia

1 reference

7 January 2021

The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity

1 reference

7 January 2021

Six months of treatment for depression: outcome and predictors of the course of illness

1 reference

7 January 2021

Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?

1 reference

7 January 2021

Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder

1 reference

7 January 2021

Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.

1 reference

7 January 2021

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

1 reference

7 January 2021

Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder

1 reference

7 January 2021

Predictors of course in obsessive-compulsive disorder

1 reference

7 January 2021

Disability and family burden in obsessive-compulsive disorder

1 reference

7 January 2021

Early response to clozapine in schizophrenia

1 reference

7 January 2021

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.20197

1 reference

18 April 2018

PubMed ID

16841343

1 reference

18 April 2018